Summary
Cannot evaluate alignment because the provided official label excerpts are incomplete (sections 1, 2, and 5 are not supplied). Several claims (indication details, dosing form/route/timing, and adverse effect frequencies) are not verifiable against the provided text.
Category Scores
Accurate Statements
Methylnaltrexone is associated with contraindication in patients with known or suspected gastrointestinal obstruction (and those at increased risk of recurrent obstruction) due to potential gastrointestinal perforation.
Section 4 CONTRAINDICATIONS: “RELISTOR is contraindicated in patients with known or suspected gastrointestinal obstruction and patients at increased risk of recurrent obstruction, due to the potential for gastrointestinal perforation [see Warnings and Precautions (5.1)].”
Serious adverse reactions described elsewhere in the labeling include gastrointestinal perforation, severe or persistent diarrhea, and opioid withdrawal.
Section 6 ADVERSE REACTIONS (serious and important adverse reactions described elsewhere): GI perforation [5.1], severe or persistent diarrhea [5.2], opioid withdrawal [5.3].
Unsupported Statements
Relistor is the brand name for methylnaltrexone.
The provided label excerpts do not include branding/ingredient identification.
Relistor syringe is used to treat opioid-induced constipation (OIC).
Section 1 INDICATIONS AND USAGE text is not provided.
Opioid-induced constipation is constipation caused by opioid pain medicines.
No label definition is provided in the supplied excerpts.
Relistor syringe is meant for people who have not gotten enough relief from constipation treatments that do not include opioid effects.
Section 1 INDICATIONS AND USAGE text is not provided.
A Relistor syringe generally refers to a pre-filled, single-use injection form of methylnaltrexone.
Section 2 DOSAGE AND ADMINISTRATION text is not provided.
The pre-filled Relistor syringe form is intended to be administered as an injection under the skin (subcutaneous).
Section 2 DOSAGE AND ADMINISTRATION text is not provided.
Methylnaltrexone is designed to act relatively quickly for opioid-induced constipation compared with waiting for constipation to resolve on its own.
No onset/timing statements are present in the provided excerpts (Section 2 not supplied).
Many patients look for a bowel movement within hours after dosing of methylnaltrexone for opioid-induced constipation.
No timing or patient-expectation/statistics are present in the provided excerpts.
Methylnaltrexone should not be used in severe gastrointestinal disease where stimulation could worsen outcomes.
The provided contraindication excerpt addresses GI obstruction; no “severe gastrointestinal disease” restriction is present in the supplied text.
Common side effects of Relistor injections include abdominal pain/cramps.
Only serious adverse reactions are shown in the provided excerpt; no “common side effects” frequency/list is provided.
Common side effects of Relistor injections include diarrhea.
Section 6 excerpt only names “severe or persistent diarrhea” as a serious reaction; “common side effects” frequency is not provided.
Common side effects of Relistor injections include nausea.
No nausea adverse reaction information is provided in the supplied excerpts.
Common side effects of Relistor injections include flatulence.
No flatulence adverse reaction information is provided in the supplied excerpts.
Injection-site reactions may occur with Relistor injections.
No injection-site adverse reaction information is provided in the supplied excerpts.
Diarrhea can become severe with methylnaltrexone and can lead to dehydration if not managed.
The supplied excerpt confirms severe/persistent diarrhea as a serious adverse reaction, but does not mention dehydration or management.
Contradictions
Low
AI Statement
Methylnaltrexone should not be used in severe gastrointestinal disease where stimulation could worsen outcomes.
Label Reference
Section 4 CONTRAINDICATIONS excerpt provided only mentions known/suspected GI obstruction and risk of recurrent obstruction due to potential GI perforation.
Important Omissions
Section 1 INDICATIONS AND USAGE details (including exact patient population/criteria and what constitutes OIC) are not provided, preventing verification of the indication-related claims.
Importance:
Moderate
Section 2 DOSAGE AND ADMINISTRATION details (formulation description, subcutaneous route, dosing instructions, timing/onset claims) are not provided.
Importance:
Moderate
Section 5 WARNINGS AND PRECAUTIONS content is not provided (only referenced). This prevents verifying claims about additional warnings/precautions beyond the contraindication excerpt.
Importance:
Moderate
Section 6 ADVERSE REACTIONS excerpt provided is limited to serious adverse reactions; label information about “common side effects” is not included, preventing verification of the listed common adverse effects.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Multiple claims are not verifiable against the provided label excerpts (indication criteria, dosing/route/form, onset expectations, and specific adverse effect frequency/contents). Unverified instruction-like details could mislead clinical or patient decision-making.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Key label sections (1, 2, and 5) and most adverse reaction details (beyond serious reactions) are not provided, making many specific claims unsupported/unverifiable.
Suggested Improvement
Provide the full FDA-approved label text for sections 1, 2, 5, and the complete adverse reactions section, then re-evaluate each claim strictly against the corresponding label statements.